Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 21, Issue 18, pp. 4165-4173
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 22, 2015
- Revision received May 18, 2015
- Accepted May 19, 2015
- Published first May 26, 2015.
Article Versions
- Previous version (May 26, 2015 - 06:25).
- Previous version (July 21, 2015 - 09:10).
- You are viewing the most recent version of this article.
Copyright & Usage
©2015 American Association for Cancer Research.
Author Information
- Marc Damelin1,*,
- Alexander Bankovich2,
- Albert Park2,
- Jorge Aguilar2,
- Wade Anderson2,
- Marianne Santaguida2,
- Monette Aujay2,
- Sarah Fong2,
- Kiran Khandke1,
- Virginia Pulito1,
- Elana Ernstoff1,
- Paul Escarpe2,
- Jeffrey Bernstein2,
- Marybeth Pysz2,
- Wenyan Zhong1,
- Erik Upeslacis1,
- Judy Lucas1,
- Justin Lucas1,
- Timothy Nichols1,
- Kathryn Loving2,
- Orit Foord2,
- Johannes Hampl2,
- Robert Stull2,
- Frank Barletta1,
- Hadi Falahatpisheh1,
- Puja Sapra1,
- Hans-Peter Gerber1, and
- Scott J. Dylla2,*
- ↵*Corresponding Authors:
Scott J. Dylla, Stemcentrx, Inc., 450 East Jamie Court, South San Francisco, CA 94080. Phone: 650-488-8547; Fax: 650-491-0116; E-mail: scott.dylla{at}stemcentrx.com; or Marc Damelin, Pfizer, Inc., 401 North Middletown Road, 200-4611, Pearl River, NY 10965. Phone: 845-602-7985; E-mail: marc.damelin{at}pfizer.com
M. Damelin and A. Bankovich share first authorship.
September 2015
Volume 21, Issue 18
Volume 21, Issue 18
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions
Jump to section
Advertisement